Over the past decade, treatment recommendations for patients with chronic lymphocytic
leukemia or small lymphocytic lymphoma (CLL/SLL) have shifted from traditional …

Simple Summary The treatment of chronic lymphocytic leukemia (CLL) has dramatically
changed following the availability of new drugs with targeted mechanisms of action …

The following ESMO Clinical Practice Guideline (CPG) has been recently updated with new
treatment recommendations and updated algorithms for managing early and advanced …

Chronic Lymphocytic Leukemia (CLL) is the most common B-cell malignancy in the Western
world, characterized by frequent relapses despite temporary remissions. Our study …

Overexpression of the anti-apoptotic protein BCL-2 is a key factor in the pathogenesis of
chronic lymphocytic leukemia (CLL) and is associated with poor clinical outcomes …

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of B cells due to
constitutive B-cell receptor (BCR) signaling, leading to apoptosis resistance and increased …

Chronic lymphocytic leukemia (CLL) is a B-cell-derived hematologic malignancy whose
progression depends on active B-cell receptor (BCR) signaling. Despite the spectacular …

Background Cholangiocarcinoma (CCA) is an aggressive cancer originating from the bile
ducts and poses a significant clinical challenge with a 5-year overall survival (OS) rate of 7 …

Pathway inhibitors targeting Bruton tyrosine kinase (BTK) and B-cell lymphoma-2 (BCL-2)
have dramatically changed the treatment landscape for both treatment-naïve and …

Randomized controlled trials (RCTs) comparing the treatment outcomes and adverse events
of venetoclax-containing regimens with chemoimmunotherapy in chronic lymphocytic …